a principal and the head of the Vanguard Investment Advisory Research Center as the lead author of the annual Advisor's Alpha study. However, once the bill is signed into law, they'll need to move ...
which met its objectives in a phase 2b Parkinson’s study, and Takeda’s TAK-431 in mid-stage testing for MSA. AstraZeneca, meanwhile, started phase 2 trials of MEDI341, an anti-alpha-syn ...